S
SeqOne
Improving patient outcome by making improved genomic analysis accessible to all
About SeqOne
SeqOne provides a genomic analysis platform for healthcare providers and molecular laboratories. The company's platform is designed to assist in the treatment of cancer, as well as rare and hereditary diseases, by analyzing next-generation sequencing (NGS) data.
The platform utilizes artificial intelligence and proprietary machine learning algorithms to interpret genomic data, identify genetic variants, and provide decision-support tools to clinicians. This is intended to streamline the diagnostic process and support the delivery of personalized medicine. The SeqOne Platform is a CE-IVD marked in vitro diagnostic medical device.
The company collaborates with other entities in the genomics space, such as Agilent and MGI Tech, to create integrated workflows, for example in liquid biopsy data analysis. SeqOne has secured significant funding, including a €20 million Series A round, to support the expansion and development of its platform.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Montpellier, France
- Employees
- 115
- Open positions
- None listed
- Dealroom signal
- 87.5/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Precision Medicine, Health Diagnostics, Spinout, Disease, Genome Engineering, Clinical Decision Support
- Technology
- Big Data
- Business model
- SaaS
- Client focus
- b2b
- Investment activity
- 2 companies, latest Sep 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | May 2025 | $22M | $88M | Omnes Capital · Supernova Invest · Elaia · Mérieux Equity Partners | ↗ |
| SERIES A✓Equity / VC | Jan 2022 | $22M | $88M | Irdi Capital Investissement · Elaia · Omnes Capital · Mérieux Equity Partners | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for SeqOne is 8.9K monthly website visits, down 11% over the last three months. SeqOne's team grew 12.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
CongenicaHinxton, United KingdomClinical genomics analytics platform
$200Mvaluation
Life & SoftLe Plessis-Robinson, France
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Other known investors5 additional known investors
INSERM
SATT AxLR
University of Montpellier
Future4Care
Korys
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SeqOne on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SeqOne’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.